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Overall, whether positive or negative, FSIHC increased conﬁdence 
82% (ranging from 50% to 99%) to 96% (60% to 100%). In those 
with metastatic colonic adenocarcinoma, changes in the conﬁdence of 
diagnosis for went from 88% (ranging from 65% to 99%) to 95% (60% 
to 100%) after FS-IHC. FS-IHC was particularly useful when samples 
were of small size and architectural features that often help distinguish 
primary from metastatic disease were lacking. The average time taken 
per test was 24 minutes at an estimated additional cost of £32 ($57). 
This technique is now part of our routine diagnostic practice, although 
is not used on every occasion as histological features alone often allow 
sufﬁcient diagnostic conﬁdence, especially in relation to metastases 
from the large bowel. However, this will be counterbalanced by the 
experience of the reporting pathologist and the case mix, so that usage 
rates in other institutions may prove higher. 
Although undoubtedly useful, FSIHC must be interpreted in the context 
of clinical and imaging presentation as well as routine histological 
features, as rare false positives can occur with TTF-1 and we have 
had one such case with an FSIHC. The time limit of 24 minutes and 
manpower issues also mean that all lesions (when multiple) cannot be 
assessed and since we started using this technique, one or more of the 
pulmonary masses have proven to be primary tumours arising synchro-
nously with metastatic disease in four cases. Even with close pre-op-
erative review, it is unlikely that such cases could be identiﬁed. Other 
groups have also shown that FSIHC for TTF-1 can be of diagnostic 
value (17) and similar techniques have been used for other antibodies 
(e.g. cytokeratins) in relation to carcinomas at other sites (18,19), but 
future usage must be weighed up against the value of the information 
that the technique provides so as not to place unnecessary workloads on 
pathology laboratories.
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Recent progress in radiologic imaging methods such as thin-section CT 
and/or high-resolution CT has improved the ability to diagnose small 
adenocarcinomas less than 2 cm in diameter. Such small-sized adeno-
carcinomas comprise two groups: replacement-type, and non-replace-
ment-type adenocarcinoma. Replacement-type adenocarcinoma, show-
ing a bronchioloalveolar carcinoma (BAC) component, is subdivided 
into three subtypes: localized BAC (LBAC) (type A), LBAC with alve-
olar collapse (type B), and LBAC with foci of ﬁbroblastic proliferation 
(type C). Non-replacement-type adenocarcinoma is also subdivided 
into three subtypes: solid adenocarcinoma with mucin formation (type 
D), tubular adenocarcinoma (type E), and papillary adenocarcinoma 
(type F). The non-replacement-type adenocarcinomas are invasive and 
have an unfavorable prognosis, whereas the replacement-type adeno-
carcinomas are a mixed group that include non-invasive carcinomas 
with an extremely favorable prognosis (types A and B, 5-year survival 
rate 100%) and early invasive or microinvasive adenocarcinoma (type 
C, 5-year survival rate 75%) (1). Most of the cases detected by CT 
screening are replacement-type adenocarcinomas, which are targets 
for reduction or limited surgery such as wedge resection or segmen-
tectomy, since they comprise a mixed population that includes tumors 
with an extremely favorable prognosis or a poor prognosis. Therefore, 
there is a need for reliable morphologic and/or immunohistochemical 
markers to discriminate less-aggressive tumors.
A number of factors are reportedly useful for prognostication of non-
small cell carcinoma and/or adenocarcinoma. However, these factors 
have not been compared sufﬁciently, especially in relation to small-
sized early adenocarcinoma. In the present study, ten immunohisto-
chemical prognostic factors reported previously ? CEA, p53, MIB1, 
p27, EGFR, pEGFR, Cox2, Neurnatin, γH2AX, and TTF-1 ? were 
selected, and their usefulness was compared using the same series of 
small-sized adenocarcinomas. Furthermore, the ratios of the BAC com-
ponent and micropapillary component in the largest cut surface of the 
tumor were examined as histologic factors. Abnormalities of the p53, 
K-ras, and EGFR genes were also examined. One hundred and thirty-
eight consecutive patients were selected. All underwent complete resec-
tion of small-sized adenocarcinomas at the National Cancer Center 
Hospital (Tokyo, Japan), and did not receive any chemotherapy and/or 
radiotherapy prior to surgery. Among the prognostic factors examined, 
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CEA, MIB1 index, and BAC component ratio were signiﬁcantly as-
sociated with prognosis. Cases stained strongly with anti-CEA antibody 
showed a signiﬁcantly less favorable outcome than CEA-negative cases 
(p=0.02). Cases with a MIB1 index of 10% or more showed a less fa-
vorable outcome than cases with a MIBI index of less than 10%. Cases 
in which the BAC component accounted for 50% or more of the tumor 
showed a better outcome than cases in which the BAC component ac-
counted for less than 50% (p<0.01). However, none of the other factors 
were related to outcome. Although numerous prognostic factors of lung 
adenocarcinoma have been reported, this study found that only three 
factors, i.e. the two immunohistochemical factors, CEA and MIB1 
index, and the histological factor, the ratio of the BAC component in 
the largest cut surface of the tumor, were signiﬁcantly associated with 
the prognosis of small-sized adenocarcinoma of the lung. 
In order to achieve desirable and evidence-based selective diagnosis of 
small-sized adenocarcinomas that are treatable by reduction surgery, a 
more extensive study to search for convenient prognostic factors should 
be performed. One trial to ﬁnd new prognostic factors for small-sized 
adenocarcinomas, especially replacement-type adenocarcinoma, has 
already been done using two representative cases that were subjected 
to polymerase chain reaction-based cDNA suppression subtractive 
hybridization (SSH) (2). One case was LBAC (type A), which shows 
an extremely favorable prognosis, and the other was LBAC with foci 
of ﬁbroblastic proliferation (type C), which is considered to be an 
invasive adenocarcinoma. Differential screening using virtual reverse 
northern hybridization and quantitative real-time reverse transcrip-
tion-polymerase chain reaction (qRT-PCR) showed that ﬁve genes 
(TncRNA, OCIAD2, ANXA2, TMED4 and LGALS4) were expressed 
at signiﬁcantly higher levels in invasive adenocarcinoma with a BAC 
component (type C) than in LBAC (type A). After in situ hybridiza-
tion and qRT-PCR analyses, the OCIAD2 gene showed signiﬁcantly 
higher expression in the tumor cells of invasive adenocarcinoma than 
in LBAC. The OCIAD2 gene was originally identiﬁed by Strausberg 
et al. in 2002 because of its sequential similarity to ovarian carcinoma 
immunoreactive antigen 1 through the National Institutes of Health 
Mammalian Gene Collection Project. OCIAD2 and OCIAD1 constitute 
the OCIA domain family. OCIAD1 was identiﬁed by Luo et al. in 2001 
by immunoscreening of an ovarian carcinoma cDNA expression library 
with ascites from ovarian cancer patients. The function of OCIAD2 has 
not been elucidated, but the protein may be immunosensitive as an anti-
gen and, like OCIAD1, could be a cancer-speciﬁc protein. Using in situ 
hybridization, the expression of OCIAD2 was examined in 56 replace-
ment-type adenocarcinomas resected at Tsukuba University Hospital 
(Ibaraki, Japan). The patients with OCIAD2 expression showed a better 
clinical outcome than those without OCIAD2 expression, and OCIAD2 
expression showed an inverse correlation with lymphatic invasion, 
blood vessel invasion and lymph node metastasis. These results suggest 
that OCIAD2 begins to be expressed during progression from in situ 
to invasive carcinoma, and is associated with a favorable prognosis of 
invasive adenocarcinoma with a BAC component (type C). 
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The histopathological classiﬁcation of thymic epithelial tumours has for 
a long time been controversial. The great morphologic variability, their 
rareness, and the lack of consistent follow-up data were arguments to 
attribute only minor value to the histopathological descriptive classiﬁ-
cation and to rely on the clinical appearance at surgery almost exclu-
sively for deciding further therapy of prognosis. A major problem for 
the introduction of a new and biology-oriented classiﬁcation was the 
general believe that in spite great morphological variability, prognosis 
would be almost the same and recurrences or metastases could not be 
predicted. Therefore, as a pragmatic approach, the usual categories of 
malignancy, namely benign tumours, low grade malignant and high 
grade malignant tumours in the thymus where classiﬁed at surgery: 
encapsulated, non-invasive tumours as benign thymoma, those with 
minimal atypia (whatever this is) as malignant thymoma type 1, and 
those with marked atypia as thymic carcinoma with increasing invasive 
and metastatic potential (6). Coming from a completely different ap-
proach, namely from the investigation of the complicated epithelial and 
lymphoepithelial structure of the thymus a “histogenetic” classiﬁcation 
has been proposed, comparing the organization of epithelial cells and 
their lymphocyte content to the normal thymic structure in 5 histo-
pathologically deﬁned categories of thymoma, as medullary thymoma, 
mixed thymoma, predominantly cortical thymoma, cortical thymoma, 
and well differentiated thymic carcinoma - and the group of thymic 
carcinomas not presenting organotypic features (5,7). The tumour types 
and their deﬁnitions were accepted as basis of the WHO classiﬁcation 
(1999), but as no agreement could be reached for the naming, the types 
were designed with letters A, B, and C (Table I).
Histogenetic classiﬁcation WHO classiﬁcation Biology
Medullary thymoma A Benign
Mixed thymoma AB Benign
Predominantly cortical thymoma B1 Borderline
Cortical thymoma B2 
Well differentiate thymic carcinoma, malignant, organotypic, usually 
no extra thoracic metastases
Well differentiated thymoma B3 
Thymic carcinomas C Malignant, low grade high grade related to 
subtypes
This classiﬁcation was discussed and updated in the new series of the 
WHO classiﬁcation of tumours pathology and genetics and basically 
conﬁrmed (WHO 2004 , 8). 
Histolopathological classiﬁcation of thymic epithelial tumours
The term thymoma is used for organotypic thymic epithelial tumours, 
characterized by similarities to the structural organization of the normal 
thymus. The histopathological typing is highly predictive for the risk of 
invasiveness, recurrence, and metastases, and for the need of adjuvant 
treatment after surgery. 
